

FORM PTO-1449  
(Rev. 2-32)U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

Serial No.

01-034

09/760,119

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:


Sarah S. Bacus

Filing Date:

01/12/2001

Group:

1642



## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
						Yes No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

1.	Dannecker et al.; Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D; Ann. Onc., Apr 1996; 7: 391 - 395.
2.	Gillett et al.; Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma; J Pathol, Jan 1999; 187(2): 200-6.
3.	Smith et al.; Primary chemotherapy in breast cancer; Biomed Pharmacother, Jan 1998; 52(3): 116-21.
4.	Srivastava et al.; Growth inhibition and activation of apoptotic gene expression by human chorionic gonadotropin in human breast epithelial cells; Anticancer Res, Nov 1998; 18(6A): 4003-10.
5.	Vollmer et al.; Down-regulation of tenascin expression by antiprogestins during terminal differentiation of rat mammary tumors; Cancer Res., Sep 1992; 52: 4642 - 4648.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.